Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 108, Issue 3-5, 2008, Pages 261-266

  Polyzos, Aristidis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; GIST; Neuroendocrine tumors; Non small cell lung cancer; Renal cell carcinoma; Sunitinib malate; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BRAIN HEMORRHAGE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PANCREATITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 38749133681     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.09.004     Document Type: Review

References (29)

1. O'Farell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
2. O'Farell A.M., Foran J.M., Fiedler W., et al. An innovative phase 1 clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 9 (2003) 5465-5476
3. Schueneman A.J., Himmelfarb E., Geng L., et al. SU1248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63 (2003) 4009-4016
4. Abrams T.J., Murray L.J., Pesenti E., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2 (2003) 1011-1021
5. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
6. Raymond E., Faivre S., Vera C., et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc. Am. Soc. Clin. Oncol. 22 (2003) 192 (abstract 769)
7. Manning W.C., Bello C.L., Deprimo S.E., et al. Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Proc. Am. Soc. Clin. Oncol. 22 (2003) 192 (abstract 768)
8. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163 (2000) 408-417
9. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13 (1995) 688-696
10. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. N. Engl. J. Med. 338 (1998) 1272-1278
11. Medical Research Council and Collaborators, Medical Research Council and Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 353 (1999) 14-17
12. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22 (2004) 454-463
13. Sükösd F., Kuroda N., Beothe T., et al. Deletion of chromosome 3p14, 2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res. 63 (2003) 455-457
14. Kondo K., Yao M., Yoshida M., et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34 (2002) 58-68
15. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
16. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7 (1994) 85-90
17. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 9700-9704
18. Illiopoulos O., Kibel A., Gay S., et al. Tumor suppression by the human von Hippel-Lindau gene product. Nat. Med. 1 (1995) 822-826
19. Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 10 (1994) 6290S-6295S
20. Kim W., and Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13 (2003) 55-60
21. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24 (2006) 16-24
22. Motzer R.J., Rini B.I., Michaelson M.D., et al. Phase II trials on SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. Proceedings of the American Society of Clinical Oncology, Annual Meeting. Orlando, FL (2005) (abstract 4508)
23. Motzer R.J., Hutson T.E., Tomczak P., et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alpha (INF-a) as first-line systemic therapy fro patients with metastatic renal cell carcinoma (m-RCC). Proceedings of the American Society of Clinical Oncology, Annual Meeting. Atlanta, GA (2006) (abstract no. LBA3, plenary presentation)
24. Maki R.G., Fletcher J.A., Heinrich M.C., et al. Results from a continual trial of SU11248 in patients with imatinib (IM) resistant gastrointestinal stromal tumor (GIST). Proceedings of the American Society of Clinical Oncology, Annual Meeting. Orlando, FL (2005) (Abstract 9011)
25. Demetri G.D., VanOosterom A.T., Blackstein M., et al. Phase 3 multicenter randomized double-blind, placebo-controlled trial of SU11248 in patients following failure of imanitinib for metastatic GIST. Proceedings of the American Society of Clinical Oncology, Annual Meeting. Orlando, FL (2005) (abstract 4000)
26. Kulke M., Lenz H.J., Meropol N.J., et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors (NETS). Proceedings of the American Society of Clinical Oncology, Annual Meeting. Orlando, FL (2005) (abstract 4008)
27. Miller K.D., Burstein H.J., Elias A.D., et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI) in patients with previously treated metastatic breast cancer (MBC). Proceedings of the American Society of Clinical Oncology, Annual Meeting. Orlando, FL (2005) (abstract 563)
28. Socinski M.A., Novello S., Sanchez J.M., et al. Efficacy and safety of sunitinib in previously treated advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology, Annual Meeting. Atlanta, GA (2006) (abstract 7001)
29. Bergers G., Song S., Meyers-Morse N., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111 (2003) 1287-1295